Sökning: "cv mortality"
Visar resultat 1 - 5 av 30 avhandlingar innehållade orden cv mortality.
1. Dietary diversity and its relation with health among the older population in Thailand
Sammanfattning : The role of dietary diversity (DD) in the health status among older people has been recognised. However, the evidence from lower-and-middle-income countries is scarce. LÄS MER
2. Vasopressin, cardiorenal disease and hydration. The vasopressin system in relation to the risk of cardiorenal disease and how vasopressin levels are affected by salt and water interventions in humans
Sammanfattning : .... LÄS MER
3. Adherence to lipid-lowering medications and cardiovascular disease prevention in type 2 diabetes mellitus
Sammanfattning : Background and aims: Globally, cardiovascular disease (CVD) is the major cause of death among patients with type 2 diabetes mellitus (T2DM). Improved control of LDL cholesterol with lipid-lowering medications and patients’ adherence to such medications have been shown associate with lower risk of CV events and mortality among T2DM patients. LÄS MER
4. Cardiovascular morbidity and metabolic signature in patients with rheumatoid arthritis
Sammanfattning : Background and objectives: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease with excess risk for cardiovascular morbidity and mortality. The treatment of RA by anti-inflammatory drugs has dramatically been improved over the resent decades. LÄS MER
5. Prevalence and Prognostic Impact of Periodontal Disease and Conventional Risk Factors in Patients with Stable Coronary Heart Disease
Sammanfattning : The purpose of this thesis was to assess the prevalence and management of established cardiovascular (CV) risk factors and the prevalence and influence of self-reported markers (number of teeth and frequency of gum bleeding) of periodontal disease (PD), a less explored CV risk factor, in patients with stable chronic coronary heart disease (CHD).We studied patients from the global STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY) trial (n=15,828), in which patients with stable chronic CHD were randomized to either darapladib or placebo. LÄS MER